SCHEMBL2537299

SCHEMBL2537299

CC(C)(C)c1ccc(-c2ccc(OCc3cccc(OC(F)(F)F)c3)c(CCC(=O)O)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 6/20 0.47
FFAR1 O14842 8/20 0.46
PTGER4 P35408 2/20 0.45
PTGER3 P43115 2/20 0.45
PTGER1 P34995 1/20 0.45
PTGER2 P43116 1/20 0.45
USP28 Q96RU2 1/20 0.44
USP25 Q9UHP3 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.44
MME P08473 1/20 0.44
AKR1B1 P15121 1/20 0.43
SLC13A5 Q86YT5 1/20 0.43
PPARD Q03181 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
GPR34 Q9UPC5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2540490 0.93 FFAR4 (0.48) FFAR4FFAR1PTGER4PTGER3PTGER1
SCHEMBL2536390 0.89 FFAR4 (0.49) FFAR4FFAR1PTGER4PTGER3PTGER1
SCHEMBL2535066 0.89 FFAR4 (0.49) FFAR4FFAR1PTGER4PTGER3PTGER1
SCHEMBL2535462 0.89 GPR34 (0.45) FFAR4USP28USP25MRGPRX4PPARD
SCHEMBL2531052 0.86 PTGER4 (0.58) FFAR4FFAR1PTGER4PTGER3PTGER1
SCHEMBL2536074 0.85 FFAR4 (0.55) FFAR4FFAR1PTGER4PTGER3PTGER1
SCHEMBL2534776 0.84 FFAR1 (0.56) FFAR4FFAR1PTGER4PTGER3PTGER1
SCHEMBL2536062 0.84 RXRA (0.53) FFAR4FFAR1PTGER4PTGER3PTGER1
SCHEMBL2538185 0.83 NPSR1 (0.49) FFAR4FFAR1PTGER4PTGER3PTGER1
SCHEMBL2533427 0.83 FFAR4 (0.51) FFAR4FFAR1PTGER4PTGER3PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044236-B2 Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-10-25 US disclosed
EP-2080751-A1 CARBOXYLIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-07-22 EP disclosed
US-20080275116-A1 Carboxilic acid derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275116-A1 Carboxilic acid derivatives SERPINE1, CTRL, SERPINC1 FFAR4 2537/4885FFAR1 710/4885PTGER4 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.